Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Trustmark National Bank Trust Department

Trustmark National Bank Trust Department grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,466 shares of the pharmaceutical company’s stock after purchasing an additional 358 shares during the period. Trustmark National Bank Trust Department’s holdings in Vertex Pharmaceuticals were worth $3,007,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Quent Capital LLC lifted its stake in shares of Vertex Pharmaceuticals by 33.0% during the 1st quarter. Quent Capital LLC now owns 399 shares of the pharmaceutical company’s stock worth $167,000 after purchasing an additional 99 shares during the period. Bessemer Group Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 269.4% during the 1st quarter. Bessemer Group Inc. now owns 12,605 shares of the pharmaceutical company’s stock worth $5,269,000 after acquiring an additional 9,193 shares during the period. EP Wealth Advisors LLC grew its holdings in Vertex Pharmaceuticals by 4.4% in the first quarter. EP Wealth Advisors LLC now owns 4,709 shares of the pharmaceutical company’s stock valued at $1,969,000 after purchasing an additional 197 shares during the period. Axxcess Wealth Management LLC increased its position in Vertex Pharmaceuticals by 33.6% during the first quarter. Axxcess Wealth Management LLC now owns 2,228 shares of the pharmaceutical company’s stock worth $931,000 after purchasing an additional 560 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 20.6% in the 1st quarter. Advisors Asset Management Inc. now owns 21,384 shares of the pharmaceutical company’s stock valued at $8,939,000 after purchasing an additional 3,656 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on VRTX shares. Truist Financial restated a “buy” rating and set a $550.00 price objective (up from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. Canaccord Genuity Group increased their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. HC Wainwright reaffirmed a “buy” rating and set a $600.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, October 21st. Oppenheimer dropped their price objective on shares of Vertex Pharmaceuticals from $550.00 to $540.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Finally, StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $499.12.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $451.23 on Thursday. Vertex Pharmaceuticals Incorporated has a 12 month low of $346.29 and a 12 month high of $519.88. The company has a fifty day moving average price of $475.38 and a two-hundred day moving average price of $472.74. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $3.67 EPS. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now directly owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 12.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The stock was sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the transaction, the chairman now owns 9,994 shares in the company, valued at $4,987,006. The trade was a 27.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,445 shares of company stock valued at $2,218,394 in the last quarter. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.